Pfizer (PFE) Total Debt (2009 - 2026)

Pfizer has disclosed Total Debt across 18 years of filings, most recently posting $64.5 billion for Q1 2026.

• In Q1 2026, Total Debt rose 3.78% year-over-year to $64.5 billion; the TTM figure through Mar 2026 stood at $64.5 billion (up 3.78% YoY), while the FY2025 annual figure was $64.8 billion, up 1.33% from the prior year.
• Total Debt eased to $64.5 billion in Q1 2026, from $64.8 billion in the prior quarter.
• Over the last five years, Total Debt for PFE reached as high as $71.9 billion in Q4 2023 and fell as low as $35.8 billion in Q4 2022.
• The 5-year median for Total Debt is $63.6 billion (2023), against an average of $57.1 billion.
• Annual changes were most pronounced in 2023 — Total Debt surged 100.64% — and 2024, when it slipped 11.05%.
• A 5-year view of Total Debt shows it stood at $35.8 billion in 2022, then surged by 100.64% to $71.9 billion in 2023, then fell by 11.05% to $63.9 billion in 2024, then advanced by 1.33% to $64.8 billion in 2025, then fell by 0.52% to $64.5 billion in 2026.
• According to Business Quant data, Total Debt over the past three periods registered $64.5 billion, $64.8 billion, and $61.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.